Page last updated: 2024-12-11

gpi 1485

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GPI 1485: a neuroimmunophilin ligand that binds FK-506-binding proteins; may be useful as antiparkinson agent or for treating erectile dysfunction arising from post-prostatectomy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9837656
CHEMBL ID	4297382
SCHEMBL ID	2006950
MeSH ID	M0466706

Synonyms (36)

Synonym
AKOS015991368
186268-78-0
(2s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
gpi 1485
gpi-1485
AKOS016340704
(2s)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarboxylic acid
l-proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-
SCHEMBL2006950
1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine carboxylic acid, 2s
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
unii-0709bvy57w
0709bvy57w ,
EG-0058
(2s)-1-(1, 2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(1.2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-l-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine-carboxylic acid
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl) -2-pyrrolidinecarboxylic acid
(2s)-1(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(1,2-dioxo-3 3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl) -2-pyrrolidine-carboxylic acid
FOPALECPEUVCTL-QMMMGPOBSA-N
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine-carboxylic acid
(2s) -1- (1,2-dioxo-3,3-dimethylpentyl) -2-pyrrolidine- carboxylic acid
(2s)-1-(l,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(3,3-dimethyl-2-oxopentanoyl)-pyrrolidine-2-carboxylic acid
(s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
mfcd02179274
DB05814
EX-A7660
gm-1485
Q27236238
CHEMBL4297382
HY-136424
CS-0129294
(s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylicacid

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	17.40 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.42 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (17.40)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (60.00%)	5.53%
Reviews	1 (20.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	1 (20.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
creatine [no description available]	3.43	1	1	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	9.25	7	5	macrolide lactam	bacterial metabolite; immunosuppressive agent
coenzyme q10 coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins. coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.	5.77	2	2	ubiquinones	antioxidant; ferroptosis inhibitor; human metabolite
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	6.42	3	3
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	3.43	1	1

Condition	Indicated	Relationship Strength	Studies	Trials
Disease Exacerbation [description not available]	0	7.52	4	4
Idiopathic Parkinson Disease [description not available]	0	10.57	10	9
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	1	12.57	10	9
Ambulation Difficulty [description not available]	0	3.43	1	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.07	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.07	1	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.07	1	0
Impotence [description not available]	0	2.93	1	0
Erectile Dysfunction The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.	0	2.93	1	0
Bilateral Headache [description not available]	0	7.46	4	4
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	7.46	4	4
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	7.46	4	4

chemdatabank.com